Shrestha S, Miao R, Wang L, Chao J, Yuce H, Wei W. Burden of atopic dermatitis in the United States: Analysis of healthcare claims data in the commercial, Medicare, and Medi-Cal databases. Adv Ther. 2017;34:1989-2006.

Wei W, Knapp K, Wang L, Chen CI, Craig GL, Ferguson K, Schwartzman S. Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: Real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy. Adv Ther. 2017;34(8):1936-52.

Kariburyo F, Xie L, Teeple A, Tan H, Ingham M. Predicting pre-emptive discussions of biologic treatment: Results from an openness and preference survey of inflammatory bowel disease patients and their prescribers. Adv Ther. 2017;34(6):1398-1410.

Knight T, Bond C, Popelar B, Wang L, Niewoehner J, Anastassopoulos K, Philbin M. Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab. Clinicoecon Outcomes Res. 2017;9:271-279.

Keshishian A, Wang Y, Xie L, Baser O. The economic impact of symptomatic menopause among low-socioeconomic women in the United States. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):305-13.

Baser O, Ganguli A, Roy S, Xie L, Cifaldi M. Impact of switching from an initial tumor necrosis factor inhibitor on health care resource utilization and costs among patients with rheumatoid arthritis. Clin Ther. 2015;37(7):1454-65.

Waljee J, Zhong L, Baser O, Fox DA, Chung KC, Yuce H. The incidence of upper and lower extremity surgery for rheumatoid arthritis a national, population-based longitudinal cohort study. J Bone Joint Surg. 2015;97(5):403-10.

Zhong L, Chung KC, Baser O, Fox DA, Yuce H, Waljee JF. Variation in rheumatoid hand and wrist surgery among Medicare beneficiaries: A population-based cohort study. J Rheumatol. 2015;42(3):429-36.

Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Direct medical costs associated with rheumatoid arthritis in Turkey: Analysis from national claims data. Rheumatol Int. 2013;33(10):2577-84.

Baser O, Baser E, Altinbas A, Burkan A. Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey. Health Econ Rev. 2013;3(5):1-7.

Baser O, Xie L, Du J. Application of probabilistic linkage: Compare health care costs among menopausal women with different symptoms by linking women’s registry and claims data. Int J Stats Med Res. 2013;2:34-9.

Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Health care costs associated with ankylosing spondylitis in Turkey: Analysis from nationwide real-world data. Int J Rheumatol. 2013;2013:1-7.

Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate to severe psoriasis using structural equation modeling. Patient Prefer Adher. 2013;7:199-205.

Gotlib J, Pardanani A, Akin C, et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013;121(13):2393-401.

Ryan RJ, Akin C, Castells M, et al. Mast cell sarcoma: A rare and potentially under-recognized diagnostic entity with specific therapeutic implications. Mod Pathol. 2013;26(4):533-43.

Baser O, Du J, Xie L, Wang H, Dysinger AH, Wang L. Derivation of severity index for rheumatoid arthritis and its association with healthcare outcomes. J Med Econ. 2012;15(5):918-24.

Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-TNF therapy. Arthritis Care Res. 2012;64(9):1282-91.

Gotlib J, Akin C. Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders. Semin Hematol. 2012;49(2):128-37.

Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215-25.

Akin C, Valent P, Metcalfe DD. Reply. J Allergy Clin Immunol. 2011 Feb 8. Hamilton MJ, Hornick JL, Akin C, et al. Mast cell activation syndrome: A newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011;128(1):147-152.e2.

Ustun C, DeRemer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res. 2011;35(9):1143-52.

Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099-104.e4.

Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. Blood. 2010;116(26):5812-7.

Valent P, Arock M, Akin C, et al. The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). Blood. 2010;116(5):850-1.

Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Refinements in response criteria in systemic mastocytosis: reply to a proposal. Eur J Haematol. 2010;85(1):88-9;author reply 90.

Simon MR, Jan M, Yee J, Nori US, Hu J, Akin C, Schwartz LB. Tryptase is not cleared by the kidneys into the urine. Int Arch Allergy Immunol. 2010;152(1):28-31.

Akin C. Anaphylaxis and mast cell disease: what is the risk?. 2010;10(1):34-8.

Akin C. Recent advances in mast cell clonality and anaphylaxis. F1000 Med Rep. 2009; 1. Sunyecz JA, Mucha L, Baser O, et al. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporosis Int. 2008;19(10):1421-9.

Foley K, Foster SA, Meadows ES, Baser O, et al. Assessment of clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med Care. 2007;45(9):902-6.

Hutchings A, Calloway M, Choy E, Hooper M, Hunter D, Jorday J, Zhang Y, Baser O, et al. The longitudinal examination of arthritis pain (LEAP) study: Relationship between weekly fluctuations in participant-rated joint pain and health outcomes. J Rheum. 2007;34(11):2291-300.

Maric I, Robyn J, Metcalfe DD, Fay MP, Carter M, Wilson T, Fu W, Stoddard J, Scott L, Hartsell M, Kirshenbaum A, Akin C, et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol. 2007;120(3):680-7.

Hungness SI, Akin C. Mastocytosis: Advances in diagnosis and treatment. Curr Allergy Asthma Rep. 2007;7(4):248-54.

Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6):435-53.

Akin C, Soto D, Brittain E, et al. Tryptase haplotype in mastocytosis: relationship to disease variant and diagnostic utility of total tryptase levels. Clin Immunol. 2007;123(3):268-71.

Valent P, Akin C, Metcalfe DD. FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest. 2007;37(2):153-4.

Kushnir-Sukhov NM, Brittain E, Reynolds JC, Akin C, Metcalfe DD. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol. 2006;139(3):265-70.

D'ambrosio C, Akin C, Wu Y, Magnusson MK, Metcalfe DD. Gene expression analysis in mastocytosis reveals a highly consistent profile with candidate molecular markers. J Allergy Clin Immunol. 2003;112(6):1162-70.

Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: State of the art. Br J Haematol. 2003;122(5):695-717.

Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: Relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol. 2003;48(4):508-16.

Akin C, Jaffe ES, Raffeld M, Kirshenbaum AS, Daley T, Noel P, Metcalfe DD. An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: -Expression of stem cell factor by lesional mast cells. Am J Clin Pathol. 2002;118(2):242-7.

Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood. 2002;100(2):661-5.

Brockow K, Scott LM, Worobec AS, Kirshenbaum A, Akin C, et al. Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: Correlation with clinical patterns of disease. Arch Dermatol. 2002;138(6):785-90.

Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression. Int Arch Allergy Immunol. 2002;127(2):137-9.

Akin C, Metcalfe DD. Surrogate markers of disease in mastocytosis. Int Arch Allergy Immunol. 2002;127(2):133-6.

Brockow K, Akin C, Huber M, Scott LM, Schwartz LB, Metcalfe DD. Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptase. J Allergy Clin Immunol. 2002;109(1):82-8.

Mekori YA, Gilfillan AM, Akin C, et al. Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL. J Clin Immunol 2001;21:171-174.

Daley T, Metcalfe DD, Akin C. Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin. Blood 2001;98:880-2.

Akin C, Kirshenbaum AS, Semere T, et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in myelomonocytic cells, T cells, and B cells from patients with mastocytosis. Exp Hematol 2000;28:140-7.

Worobec AS, Akin C, Scott LM, Metcalfe DD. Mastocytosis complicating pregnancy. Obstet Gynecol. 2000;95:391-5.

Akin C, Schwartz LB, Kitoh T, et al. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: Relationships to disease severity and bone marrow pathology. Blood. 2000;96:1267-73.

Worobec AS, Akin C, Scott LM, Metcalfe DD. Cytogenetic abnormalities and their lack of relationship to the Asp816Val c-kit mutation in the pathogenesis of  mastocytosis. J Allergy Clin Immunol 1998;102:523-4.

To request article copies, please email us at This email address is being protected from spambots. You need JavaScript enabled to view it.